Long term dual antiretroviral therapy: A real life retrospective countrywide Israeli study

<h4>Aim</h4> Combined antiretroviral treatment (cART) traditionally consists of three antiretroviral medications, while two-drug regimens (2DR), historically used infrequently, recently been suggested to be non-inferior to three-drug regimens, is emerging as a potential treatment option...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Daniel David, Eynat Kedem, Dan Turner, Itzchak Levy, Daniel G. Elbirt, Eduardo Shahar, Valery Istumin, Orna Mor, Michal Chowers, Hila Elinav
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/560a08575edf43fc812a882bb4aaecb5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:560a08575edf43fc812a882bb4aaecb5
record_format	dspace
spelling	oai:doaj.org-article:560a08575edf43fc812a882bb4aaecb52021-11-04T06:49:31ZLong term dual antiretroviral therapy: A real life retrospective countrywide Israeli study1932-6203https://doaj.org/article/560a08575edf43fc812a882bb4aaecb52021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555785/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Aim</h4> Combined antiretroviral treatment (cART) traditionally consists of three antiretroviral medications, while two-drug regimens (2DR), historically used infrequently, recently been suggested to be non-inferior to three-drug regimens, is emerging as a potential treatment option and is currently a recommended option for treatment initiation in many guidelines. <h4>Purpose</h4> Characterize the indications and clinical efficacy of 2DR use at a real-life setting in a nation-wide survey. <h4>Methods</h4> A cross-sectional survey of Israeli patients treated by 2DR until July 2019, included demographic, immunologic, virologic, genotypic and biochemical/metabolic parameters at diagnosis, ART initiation, 2DR initiation and following 24, 48, 96 and 144 weeks of 2DR treatment. <h4>Results</h4> 176 patients were included in the study. In contrast to historical data implicating ART resistance and adverse effects as the major reasons leading to 2DR switching, treatment simplification was the main reason leading to 2DR treatment in 2019. 2DR that included INSTI and PI were more commonly used in cases of drug resistance, while a combination of INSTI and NNRTI was used in all other 2DR indications. A switch to 2DR induced a mean CD4 T cell increase from 599 cells/μl at treatment initiation to 680 cells/μl at 96 weeks of treatment p<0.001 and viral suppression improvement from 73.9% at initiation to 87.0% at 48 weeks of treatment (p = 0.004). PI and INSTI 2DR was inferior in suppressing viral levels compared to other 2DRs but used for subset of more complex patients. <h4>Conclusions</h4> 2DR in a large-scale real-life nation-wide survey proved to be safe and effective. Most 2DRs, other than PI and INSTI, were similarly effective in suppressing HIV viremia and in elevating CD4 T cell counts.Daniel DavidEynat KedemDan TurnerItzchak LevyDaniel G. ElbirtEduardo ShaharValery IstuminOrna MorMichal ChowersHila ElinavPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Daniel David Eynat Kedem Dan Turner Itzchak Levy Daniel G. Elbirt Eduardo Shahar Valery Istumin Orna Mor Michal Chowers Hila Elinav Long term dual antiretroviral therapy: A real life retrospective countrywide Israeli study
description	<h4>Aim</h4> Combined antiretroviral treatment (cART) traditionally consists of three antiretroviral medications, while two-drug regimens (2DR), historically used infrequently, recently been suggested to be non-inferior to three-drug regimens, is emerging as a potential treatment option and is currently a recommended option for treatment initiation in many guidelines. <h4>Purpose</h4> Characterize the indications and clinical efficacy of 2DR use at a real-life setting in a nation-wide survey. <h4>Methods</h4> A cross-sectional survey of Israeli patients treated by 2DR until July 2019, included demographic, immunologic, virologic, genotypic and biochemical/metabolic parameters at diagnosis, ART initiation, 2DR initiation and following 24, 48, 96 and 144 weeks of 2DR treatment. <h4>Results</h4> 176 patients were included in the study. In contrast to historical data implicating ART resistance and adverse effects as the major reasons leading to 2DR switching, treatment simplification was the main reason leading to 2DR treatment in 2019. 2DR that included INSTI and PI were more commonly used in cases of drug resistance, while a combination of INSTI and NNRTI was used in all other 2DR indications. A switch to 2DR induced a mean CD4 T cell increase from 599 cells/μl at treatment initiation to 680 cells/μl at 96 weeks of treatment p<0.001 and viral suppression improvement from 73.9% at initiation to 87.0% at 48 weeks of treatment (p = 0.004). PI and INSTI 2DR was inferior in suppressing viral levels compared to other 2DRs but used for subset of more complex patients. <h4>Conclusions</h4> 2DR in a large-scale real-life nation-wide survey proved to be safe and effective. Most 2DRs, other than PI and INSTI, were similarly effective in suppressing HIV viremia and in elevating CD4 T cell counts.
format	article
author	Daniel David Eynat Kedem Dan Turner Itzchak Levy Daniel G. Elbirt Eduardo Shahar Valery Istumin Orna Mor Michal Chowers Hila Elinav
author_facet	Daniel David Eynat Kedem Dan Turner Itzchak Levy Daniel G. Elbirt Eduardo Shahar Valery Istumin Orna Mor Michal Chowers Hila Elinav
author_sort	Daniel David
title	Long term dual antiretroviral therapy: A real life retrospective countrywide Israeli study
title_short	Long term dual antiretroviral therapy: A real life retrospective countrywide Israeli study
title_full	Long term dual antiretroviral therapy: A real life retrospective countrywide Israeli study
title_fullStr	Long term dual antiretroviral therapy: A real life retrospective countrywide Israeli study
title_full_unstemmed	Long term dual antiretroviral therapy: A real life retrospective countrywide Israeli study
title_sort	long term dual antiretroviral therapy: a real life retrospective countrywide israeli study
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/560a08575edf43fc812a882bb4aaecb5
work_keys_str_mv	AT danieldavid longtermdualantiretroviraltherapyarealliferetrospectivecountrywideisraelistudy AT eynatkedem longtermdualantiretroviraltherapyarealliferetrospectivecountrywideisraelistudy AT danturner longtermdualantiretroviraltherapyarealliferetrospectivecountrywideisraelistudy AT itzchaklevy longtermdualantiretroviraltherapyarealliferetrospectivecountrywideisraelistudy AT danielgelbirt longtermdualantiretroviraltherapyarealliferetrospectivecountrywideisraelistudy AT eduardoshahar longtermdualantiretroviraltherapyarealliferetrospectivecountrywideisraelistudy AT valeryistumin longtermdualantiretroviraltherapyarealliferetrospectivecountrywideisraelistudy AT ornamor longtermdualantiretroviraltherapyarealliferetrospectivecountrywideisraelistudy AT michalchowers longtermdualantiretroviraltherapyarealliferetrospectivecountrywideisraelistudy AT hilaelinav longtermdualantiretroviraltherapyarealliferetrospectivecountrywideisraelistudy
_version_	1718445089165934592

Long term dual antiretroviral therapy: A real life retrospective countrywide Israeli study

Ejemplares similares